Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.puhe.2021.01.021

http://scihub22266oqcxt.onion/10.1016/j.puhe.2021.01.021
suck pdf from google scholar
33774512!7879028!33774512
unlimited free pdf from europmc33774512    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid33774512      Public+Health 2021 ; 193 (?): 113-115
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection #MMPMID33774512
  • Murillo-Zamora E; Mendoza-Cano O; Delgado-Enciso I; Hernandez-Suarez CM
  • Public Health 2021[Apr]; 193 (?): 113-115 PMID33774512show ga
  • OBJECTIVE: The aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. STUDY DESIGN: This is a nationwide retrospective cohort study that was conducted in Mexico. METHODS: Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection. RESULTS: The risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RR(per year) = 1.007, 95% CI = 1.003-1.010), comorbidities (namely, obesity [RR = 1.12, 95% CI = 1.01-1.24], asthma [RR = 1.26, 95% CI = 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI = 1.07-1.38]), and previous severe laboratory-confirmed coronavirus disease 2019 (RR = 1.20, 95% CI = 1.03-1.39). CONCLUSIONS: To the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.
  • |*Severity of Illness Index[MESH]
  • |Adult[MESH]
  • |Aged[MESH]
  • |COVID-19 Nucleic Acid Testing[MESH]
  • |COVID-19/*diagnosis/epidemiology/therapy[MESH]
  • |Comorbidity[MESH]
  • |Female[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Laboratories[MESH]
  • |Male[MESH]
  • |Mexico/epidemiology[MESH]
  • |Middle Aged[MESH]
  • |Reinfection/*diagnosis/therapy[MESH]
  • |Retrospective Studies[MESH]
  • |Risk Factors[MESH]
  • |SARS-CoV-2/*isolation & purification[MESH]
  • |Symptom Assessment[MESH]
  • |Treatment Outcome[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box